Contrasting TherapeuticsMD (TXMD) and The Competition
TherapeuticsMD (NASDAQ: TXMD) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare TherapeuticsMD to related businesses based on the strength of its risk, dividends, institutional ownership, analyst recommendations, earnings, valuation and profitability.
Volatility & Risk
TherapeuticsMD has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, TherapeuticsMD’s competitors have a beta of 0.89, suggesting that their average share price is 11% less volatile than the S&P 500.
Earnings and Valuation
This table compares TherapeuticsMD and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|TherapeuticsMD||$18.26 million||-$88.99 million||-11.09|
|TherapeuticsMD Competitors||$2.40 billion||$905.93 million||-0.22|
TherapeuticsMD’s competitors have higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
71.6% of TherapeuticsMD shares are held by institutional investors. Comparatively, 66.8% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 23.9% of TherapeuticsMD shares are held by insiders. Comparatively, 11.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares TherapeuticsMD and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and recommmendations for TherapeuticsMD and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TherapeuticsMD presently has a consensus price target of $14.88, suggesting a potential upside of 191.67%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 20.66%. Given TherapeuticsMD’s stronger consensus rating and higher probable upside, equities analysts plainly believe TherapeuticsMD is more favorable than its competitors.
TherapeuticsMD beats its competitors on 7 of the 12 factors compared.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.
Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.